Antiestrogen therapy with agents such as tamoxifen (TAM) and aromatase inhibitors is the cornerstone of systemic breast cancer therapy, which has significantly improved the survival of women with hormone receptor-positive (HR) breast cancers [2–4]. The gene discussed is NR4A1; the disease is breast cancer.